To all participants of the 9th ACOS

It is our great honor to inform you that KOBAYASHI FOUNDATION FOR CANCER RESEARCH will give a special award to the outstanding researchers who made abstract submission from Asian countries except Japan. So, we are deeply welcome your abstract submission which is remarkable social contributions to cancer chemotherapy. Please check the Memorandum of Kobayashi Foundation Award. The candidate abstracts will be all submitted papers from either oral and poster presentation.
If there is any question concerning about this new award, please don't hesitate to inform us. We are looking forward to hearing from you and seeing you again at Gifu, Japan. Depending on the above new award, the 9th ACOS local organizing committee had extended the dead line of abstract submission to May 1, 2010.

 

Memorandum of Kobayashi Foundation Award

1. Purpose of this Award

Public Interest Incorporated Foundations, KOBAYASHI FOUNDATION FOR CANCER RESEARCH will give an award to the outstanding researchers who made remarkable social contributions to cancer chemotherapy in Asian countries other than Japan.

2. How to apply

Abstract presenters of the 9th International Conference of the Asian Clinical Oncology Society (ACOS), who agree with the purpose of this award and wish to apply, can be proceed the application on the ACOS official website.

3. Selection Process

The selection committee composed of cancer chemotherapy experts will screen the presentation abstracts and select the award winner.

4. Award winner and Prize

About 15 Asian researchers from all candidates will be selected and awarded (JPY 2million in total).
Oral Presenters: 6 researchers (JPY 200,000 each)
Poster Presenters: 8 researchers (JPY 100,000 each)

5. Result Announcements

Selection Policy

1. Kobayashi Foundation Award is for researchers in Asian countries except Japan.

2. All abstracts applied for the award are divided into oral and poster abstracts, and the selection committee gives scores to them from 1 (the lowest) to 5 (the highest).

3. The researchers in many Asian countries are given the award by the purpose of our foundation, which is to contribute to the development of cancer treatment in Asian countries. Therefore, only one for every ten abstract is selected and the maximum number of winners is three per country.

4. The abstracts about cancer chemotherapy have a priority if there is not much difference in total scores.

5. The chairman of the selection committee doesn’t evaluate and give scores to the abstracts but makes a final decision on the winners.

6. If there are abstracts with same points, the decision is left to the chairman of the selection committee.

The name of Winner, title of abstracts and his country

(1) Oral Presentation : 6 researches (JPY 200,000 each) ( ) : number of abstract submission

1.Hypermethylation of the RECK gene predicts poor prognosis in oral squamous cell carcinomas (32) DEPARTMENT OF PLASTIC AND MAXILLOFACIAL SURGERY, HANOI VN-CB HOSPITAL, VIETNAM1, Department of Oral and Maxillofacial sciences, Graduate school of Medicine, Gifu university, Japan2, Department of Tumor Pathology, Graduate School of Medicine, Gifu University, Japan3, LONG KHANH NGUYEN¹ ,² , Toshiyuki Shibata² , Akira Hara³ , Keizo Kato² , Tomomi Yamashita² , Makoto Toida² , Hiroki Makita²

2.A MULTICENTRE PHASE II FEASIBILITY STUDY EVALUATING GEMCITABINE /VINORELBINE/PREDNISOLONE COMBINATION CHEMOTHERAPY IN RELAPSED /REFRACTORY HODGKIN's DISEASE (33) Oncology Department, Combined Military Hospital and Medical College, Lahore¹ , Oncology Department, Mayo Hospital, King Edward Medical University Lahore² , Oncology Department, Allied Hospital, Faialabad Medical College, Faisalabad³ , Naeem Naqi¹ , Shaharyar Ahmad² , Ijaz Shah³

3. Quality assurance of the KROG 08-06 study, Phase III randomized trial to investigate the role of internal mammary lymph node irradiation for breast cancer patients (150) Department of Radiation Oncology, Severance Hospital, Yonsei University Health System, Korea¹, Department of Radiation Oncology, Asan Medical Center, Korea², Department of Radiation Oncology, Samsung Medical Center, Korea³ , Proton Therapy Center, National Cancer Center, Korea⁴ , Department of Radiation Oncology, Chonnam National University Hospital, Korea⁵, Department of Radiation Oncology, Dong-A University Hospital, Korea⁶,Department of Radiation Oncology, Gangnam Severance Hospital, Korea⁷, Department of Radiation Oncology, Ewha Womans University Mokdong Hospital, Korea⁸, Department of Radiation Oncology, Pusan National University Hospital, Korea⁹,Department of Radiation Oncology, Inha University Hospital, Korea ¹⁰,Department of Radiation Oncology, St. Vincent’s Hospital, Korea Yoonsun Chung¹, Yong Bae Kim¹, Su Ssan Kim² , Hee Rim Nam³, Kyung Hwan Shin⁴, Sung-Ja Ahn⁵, Hyung-Sik Lee⁶, Ik Jae Lee⁷, Hyun Suk Suh⁸, Dong Won Kim⁹, Woo Chul Kim¹⁰, Sung Hwan Kim¹¹, Chang-Ok Suh¹

4. High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with Peripheral T-cell Lymphoma: Transplantation in the Complete Remission to the First-line Chemotherapy may be the best timing (268) Department of Medical Oncology,Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), Beijing China¹, Department of Radiotherapy, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), Beijing China Lin Gui¹, Yuankai Shi¹, Xiaohui He¹, Xiaohong Han¹, Shengyu Zhou¹, Kehuan Luo¹, Shikai Wu¹, Feng Pan¹, Peng Liu¹, Jiangliang Yang¹, Yingheng Lei², Hongzhi Zhang², Changgong Zhang¹, Sheng Yang¹, Yan Qin¹

5. Detection of Somatic Mitochondrial DNA Mutations in Different Grades of Human Astrocytoma and its Recurrence Tissues (422) Department of Neurosurgery, Chang Gung Memorial Hospital, Tao-Yuan, Taiwan¹, Chih Lung Lin¹

6. TROGLITAZONE MODULATES DOXORUBICIN DRUG RESISTANCE THROUGH MDR1, p53, IL8 and ECOP (442) DEPT. OF MOLECULAR ONCOLOGY, CANCER INSTITUTE (WIA), ADYAR, CHENNAI, INDIA¹, THANGARAJAN RAJKUMAR¹, TITHI PARIJA¹, MANOHARAN YAMUNA¹

(2) Poster Presentation : 8 researches (JPY 100,000 each)
( ) : number of abstract submission

1.Quality of Life of Colorectal cancer stoma patients at the Cancer Institute, Philippine General Hospital (6) Section of Medical Oncology, Philippine General Hospital¹, Sherry Athena D. Ruste1, Corazon A. Ngelangel¹, Susano Tanael¹

2.QUANTITATIVE COX2 PROMOTER METHYLATION ANALYSIS IN GASTRIC CARCINOMA (67) Department of Surgery, Chonnam National University Medical School¹, Department of Pathology, Chonnam National University Medical School Jae Kyoon Joo¹, Dong Yi Kim¹, Jae Hyuk Lee², Chang Hyun Kim¹, Ho Gun Kim¹, Seong Yeob Ryu¹, Chan Yong Park¹

3.Serial Changes in the Expression of Breast Cancer-Related Proteins In Response to Neoadjuvant Chemotherapy (282) Department of Haematology-Oncology, National University Health System, Singapore¹, Department of Pathology, National University Health System, Singapore², Department of Surgery, National University Health System, Singapore³, Benjamin YS Chuah¹, Amanda Charltonv², Manuel Salto-Tellez², Philip Iau³, Thomas Putti², Chiung-Ing Wong¹, Sing-Huang Tan¹, Boon-Cher Goh¹, Soo-Chin Lee¹

4. Helicobacter Pylori Infection as an Independent Prognostic Factor for Locally Advanced Gastric Cancer Patients Treated With Adjuvant Chemotherapy After Curative Resection (308) Department of Hematology-Oncology, Ajou University School of Medicine, Korea (Rep.).¹, Seok Y Kang¹, Hyun W Lee¹,

5.A randomized phase II study of irinotecan monotherapy versus irinotecan plus 5-fluorouracil/leucovorin combination as a salvage chemotherapy in previously treated patients with advanced/metastatic gastric cancer (382) Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Hospital, Incheon, Korea¹, Department of General Surgery², Division of Hematology/Oncology, Department of Medicine, Sungkyunkwan University Samsung Medical Center, Seoul³, Sun Jin Sym¹, Yae Min Park¹, Se Hoon Park³, Junsik Hong¹, Jinny Park¹, Eun Kyung

6. CDA-2 Inhibits Growth of C6 Glioma Cells Accompanied With Down Regulation of DNA Methyltransferase 1 and Inhibition of Platelet-Derived Growth Factor Receptor and Akt/PKB Signaling (390) Cancer center, Taipei Medical University-Wan Fang Hospital, Taipei, Taiwan¹, National Institute of Cancer Research, National Health Research Institutes, Taipei, Taiwan Gi-Ming Lai¹, Shuang-En Chuang², Ya-Yu Yang², Chuan-Feng Yeh², Tsai-Shu Hu¹, Chih-Jung Yao¹

7. Expression of Metadherin mRNA in peripheral blood of breast cancer patients and its clinical significance (397) Department of Oncology, General Hospital of Shenyang Military Region,China¹, Department of Oncology, General Hospital of Shenyang Military Region,China², Department of Oncology, General Hospital of Shenyang Military Region,China³, Bing li¹, Xiao Dong Xie², Zhao Zhe Liu³

8. Identification of predictive factors in the radiosensitivity of glioma cells: special focus on angiogenesis, proliferation and apoptosis as tumor biological behaviours (415) Department of Neurosurgery, Cipto Mangunkusumo General Hospital, Jakarta, Indonesia¹, Department of Radiotherapy, Cipto Mangunkusumo General Hospital, Jakarta, Indonesia Renindra, A Aman¹, Soehartati Gondhowiardjo²,

6. Award Ceremony

The award will be presented at the closing ceremony of the 9th ACOS.

7. Contacts

・ Office of the 9th International Conferences of ACOS
E-mail: secretariat@acos2010.org

・ Kobayashi Foundation for Cancer Research
TEL: +81-3-3293-2125
E-mail: info@kficc.or.jp